Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching From Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in Virologically Suppressed Adults in Haiti

NCT04311957 is registered in ClinicalTrials.gov with Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic as lead sponsor.

NCT NCT04311957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04311957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching From Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in Virologically Suppressed Adults in Haiti
Lead sponsor
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2020
Completion date
November 30, 2022
Enrollment
386 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiretroviral therapy, hiv-1-infection